Advertisement
Advertisement
U.S. markets open in 9 hours 28 minutes
Advertisement
Advertisement
Advertisement
Advertisement

LexaGene Holdings Inc. (LXXGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0966-0.0083 (-7.95%)
At close: 03:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.1050
Open0.1043
BidN/A x N/A
AskN/A x N/A
Day's Range0.0928 - 0.1043
52 Week Range0.0820 - 0.4780
Volume117,678
Avg. Volume129,932
Market Cap13.998M
Beta (5Y Monthly)1.56
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateJun 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for LXXGF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • LEXAGENE HOLDINGS INC
    Analyst Report: Becton, Dickinson and CompanyBecton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    LexaGene Announces Filing of Financial Statements, Revocation of MCTO & the Granting of Incentive Equity Awards to Employees

    BEVERLY, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated PCR-based syndromic testing in veterinary clinics, is pleased to announce that the Company has filed its Canadian audited financial statements for the year ended February 28, 2022 and the related management's discussion and analysis and certifications and the unaudited interim

  • GlobeNewswire

    LexaGene Completes Multi-Center Validation Study Using MiQLab® System for Diagnosing Urinary Tract Infections

    BEVERLY, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated PCR-based syndromic testing in veterinary clinics, provides a brief summary of preliminary data collected during a clinical validation study conducted at two of the top five veterinary universities in the nation.1 The study was led by Professor Dr. Jane Sykes BVSc (Hons), PhD,

  • GlobeNewswire

    LexaGene Provides MCTO Update

    BEVERLY, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated PCR-based syndromic testing in veterinary clinics, provides an update regarding the previously announced management cease trade order (the “MCTO”) voluntarily requested by the Company and issued by the British Columbia Securities Commission on June 30, 2022 in connection with t

Advertisement
Advertisement